Clinical Trials Unit
Stanford University School of Medicine's Center for Advanced Dermatologic Investigation is the Dermatology Department's clinical trials unit.
The Center is home to 12-15 ongoing clinical studies, investigating the safety and efficacy of new and currently available drugs and over-the-counter medications. The Center works with Stanford's own panel on medical research, leading pharmaceutical companies,and the Food and Drug Administration to safely and ethically expand the medical field's knowledge of dermatologic treatments. New studies begin regularly, and the Center continues to recruit patients with skin aging, sun damage, skin cancer (including basal cell carcinomas), psoriasis, atopic dermatitis, rosacea, and other dermatologic diseases for ongoing studies.
Skin Aging Studies
We seek to understand the human aging processes as it relates to skin on a fundamental level. To this end, our studies focus on clinical and translational research efforts ranging from: (1) the analysis of gene changes which predispose individuals to exceptionally youthful skin to (2) molecular signatures that may be biomarkers for aging skin to (3) the careful study of new candidate agents which might affect the skin aging process.
Nonmelanoma Skin Cancer
Recent advances in our understanding of basal cell skin cancer biology have enabled the development of cutting edge study drugs which combat tumor growth. We are currently home to a number of clinical trials at the forefront of potential therapy for advanced or metastatic basal cell cancer. In addition, we seek to understand the biology of basal cell skin cancers and to identify molecular predictors for treatment success.
Acne Rosecea
This is a common and frustrating chronic inflammatory condition of the face, usually affecting older individuals. The causes of this complex condition are the subject of much study. Our clinical studies seek to identify new topical or oral medications to improve the symptoms of acne rosacea.
Contact
For more information, please email dermtrials@stanford.edu
Featured Clinical Trials
A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO)
This Phase 3 study will evaluate the efficacy, durability, and safety of KSI-301 compared to aflibercept, in participants with macular edema due to treatment-naïve branch (BRVO) or central retinal vein occlusion (CRVO).
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: KSI-301
- drug: Aflibercept
- other: Sham Procedure
Eligibility
Inclusion Criteria:
1. Signed informed consent prior to participation in the study.
2. Treatment-naïve macular edema of 6 months duration or less due to CRVO or BRVO.
Participants with hemiretinal vein occlusion will be included as CRVO.
3. BCVA ETDRS letter score between 80 and 25 (20/25 to 20/320 Snellen equivalent),
inclusive in the Study Eye.
4. CST of ≥ 320 microns on SD-OCT (Heidelberg Spectralis or equivalent on other OCT
instruments) as determined by the Reading Center
5. Decrease in vision determined by the Investigator to be primarily the result of ME
secondary to RVO.
6. Other protocol-specified inclusion criteria may apply.
Exclusion Criteria:
1. Macular edema in the Study Eye for reasons other than RVO
2. Active iris or angle neovascularization, neovascular glaucoma, neovascularization of
the optic disc, retinal neovascularization or vitreous hemorrhage in the Study Eye.
3. Uncontrolled glaucoma in the Study Eye.
4. Active retinal disease other than the condition under investigation in the Study Eye.
5. Any history or evidence of a concurrent ocular condition present, that in the opinion
of the Investigator could require either medical or surgical intervention alter visual
acuity during the study
6. Active or suspected ocular or periocular infection or inflammation
7. Any prior use of an approved or investigational treatment for macular edema secondary
to RVO in the Study Eye (e.g. anti-VEGF, intraocular or periocular steroids, macular
laser photocoagulation).
8. Women who are pregnant or lactating or intending to become pregnant during the study.
9. Uncontrolled blood pressure defined as a systolic value ≥ 180 mmHg or diastolic value
≥100 mmHg while at rest
10. Recent history (within the 6 months prior to screening) of myocardial infarction,
stroke, transient ischemic attack, acute congestive heart failure or any acute
coronary event.
11. History of a medical condition that, in the judgment of the Investigator, would
preclude scheduled study visits, completion of the study, or a safe administration of
investigational product.
12. Other protocol-specified exclusion criteria may apply.
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Recruiting
Psoriasis Clinical Trials
A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO)
This Phase 3 study will evaluate the efficacy, durability, and safety of KSI-301 compared to aflibercept, in participants with macular edema due to treatment-naïve branch (BRVO) or central retinal vein occlusion (CRVO).
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: KSI-301
- drug: Aflibercept
- other: Sham Procedure
Eligibility
Inclusion Criteria:
1. Signed informed consent prior to participation in the study.
2. Treatment-naïve macular edema of 6 months duration or less due to CRVO or BRVO.
Participants with hemiretinal vein occlusion will be included as CRVO.
3. BCVA ETDRS letter score between 80 and 25 (20/25 to 20/320 Snellen equivalent),
inclusive in the Study Eye.
4. CST of ≥ 320 microns on SD-OCT (Heidelberg Spectralis or equivalent on other OCT
instruments) as determined by the Reading Center
5. Decrease in vision determined by the Investigator to be primarily the result of ME
secondary to RVO.
6. Other protocol-specified inclusion criteria may apply.
Exclusion Criteria:
1. Macular edema in the Study Eye for reasons other than RVO
2. Active iris or angle neovascularization, neovascular glaucoma, neovascularization of
the optic disc, retinal neovascularization or vitreous hemorrhage in the Study Eye.
3. Uncontrolled glaucoma in the Study Eye.
4. Active retinal disease other than the condition under investigation in the Study Eye.
5. Any history or evidence of a concurrent ocular condition present, that in the opinion
of the Investigator could require either medical or surgical intervention alter visual
acuity during the study
6. Active or suspected ocular or periocular infection or inflammation
7. Any prior use of an approved or investigational treatment for macular edema secondary
to RVO in the Study Eye (e.g. anti-VEGF, intraocular or periocular steroids, macular
laser photocoagulation).
8. Women who are pregnant or lactating or intending to become pregnant during the study.
9. Uncontrolled blood pressure defined as a systolic value ≥ 180 mmHg or diastolic value
≥100 mmHg while at rest
10. Recent history (within the 6 months prior to screening) of myocardial infarction,
stroke, transient ischemic attack, acute congestive heart failure or any acute
coronary event.
11. History of a medical condition that, in the judgment of the Investigator, would
preclude scheduled study visits, completion of the study, or a safe administration of
investigational product.
12. Other protocol-specified exclusion criteria may apply.
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Recruiting
Dermatology Clinical Trials
A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO)
This Phase 3 study will evaluate the efficacy, durability, and safety of KSI-301 compared to aflibercept, in participants with macular edema due to treatment-naïve branch (BRVO) or central retinal vein occlusion (CRVO).
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: KSI-301
- drug: Aflibercept
- other: Sham Procedure
Eligibility
Inclusion Criteria:
1. Signed informed consent prior to participation in the study.
2. Treatment-naïve macular edema of 6 months duration or less due to CRVO or BRVO.
Participants with hemiretinal vein occlusion will be included as CRVO.
3. BCVA ETDRS letter score between 80 and 25 (20/25 to 20/320 Snellen equivalent),
inclusive in the Study Eye.
4. CST of ≥ 320 microns on SD-OCT (Heidelberg Spectralis or equivalent on other OCT
instruments) as determined by the Reading Center
5. Decrease in vision determined by the Investigator to be primarily the result of ME
secondary to RVO.
6. Other protocol-specified inclusion criteria may apply.
Exclusion Criteria:
1. Macular edema in the Study Eye for reasons other than RVO
2. Active iris or angle neovascularization, neovascular glaucoma, neovascularization of
the optic disc, retinal neovascularization or vitreous hemorrhage in the Study Eye.
3. Uncontrolled glaucoma in the Study Eye.
4. Active retinal disease other than the condition under investigation in the Study Eye.
5. Any history or evidence of a concurrent ocular condition present, that in the opinion
of the Investigator could require either medical or surgical intervention alter visual
acuity during the study
6. Active or suspected ocular or periocular infection or inflammation
7. Any prior use of an approved or investigational treatment for macular edema secondary
to RVO in the Study Eye (e.g. anti-VEGF, intraocular or periocular steroids, macular
laser photocoagulation).
8. Women who are pregnant or lactating or intending to become pregnant during the study.
9. Uncontrolled blood pressure defined as a systolic value ≥ 180 mmHg or diastolic value
≥100 mmHg while at rest
10. Recent history (within the 6 months prior to screening) of myocardial infarction,
stroke, transient ischemic attack, acute congestive heart failure or any acute
coronary event.
11. History of a medical condition that, in the judgment of the Investigator, would
preclude scheduled study visits, completion of the study, or a safe administration of
investigational product.
12. Other protocol-specified exclusion criteria may apply.
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Recruiting
Pediatric Dermatology Clinical Trials
A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO)
This Phase 3 study will evaluate the efficacy, durability, and safety of KSI-301 compared to aflibercept, in participants with macular edema due to treatment-naïve branch (BRVO) or central retinal vein occlusion (CRVO).
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: KSI-301
- drug: Aflibercept
- other: Sham Procedure
Eligibility
Inclusion Criteria:
1. Signed informed consent prior to participation in the study.
2. Treatment-naïve macular edema of 6 months duration or less due to CRVO or BRVO.
Participants with hemiretinal vein occlusion will be included as CRVO.
3. BCVA ETDRS letter score between 80 and 25 (20/25 to 20/320 Snellen equivalent),
inclusive in the Study Eye.
4. CST of ≥ 320 microns on SD-OCT (Heidelberg Spectralis or equivalent on other OCT
instruments) as determined by the Reading Center
5. Decrease in vision determined by the Investigator to be primarily the result of ME
secondary to RVO.
6. Other protocol-specified inclusion criteria may apply.
Exclusion Criteria:
1. Macular edema in the Study Eye for reasons other than RVO
2. Active iris or angle neovascularization, neovascular glaucoma, neovascularization of
the optic disc, retinal neovascularization or vitreous hemorrhage in the Study Eye.
3. Uncontrolled glaucoma in the Study Eye.
4. Active retinal disease other than the condition under investigation in the Study Eye.
5. Any history or evidence of a concurrent ocular condition present, that in the opinion
of the Investigator could require either medical or surgical intervention alter visual
acuity during the study
6. Active or suspected ocular or periocular infection or inflammation
7. Any prior use of an approved or investigational treatment for macular edema secondary
to RVO in the Study Eye (e.g. anti-VEGF, intraocular or periocular steroids, macular
laser photocoagulation).
8. Women who are pregnant or lactating or intending to become pregnant during the study.
9. Uncontrolled blood pressure defined as a systolic value ≥ 180 mmHg or diastolic value
≥100 mmHg while at rest
10. Recent history (within the 6 months prior to screening) of myocardial infarction,
stroke, transient ischemic attack, acute congestive heart failure or any acute
coronary event.
11. History of a medical condition that, in the judgment of the Investigator, would
preclude scheduled study visits, completion of the study, or a safe administration of
investigational product.
12. Other protocol-specified exclusion criteria may apply.
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Recruiting
A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO)
This Phase 3 study will evaluate the efficacy, durability, and safety of KSI-301 compared to aflibercept, in participants with macular edema due to treatment-naïve branch (BRVO) or central retinal vein occlusion (CRVO).
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: KSI-301
- drug: Aflibercept
- other: Sham Procedure
Eligibility
Inclusion Criteria:
1. Signed informed consent prior to participation in the study.
2. Treatment-naïve macular edema of 6 months duration or less due to CRVO or BRVO.
Participants with hemiretinal vein occlusion will be included as CRVO.
3. BCVA ETDRS letter score between 80 and 25 (20/25 to 20/320 Snellen equivalent),
inclusive in the Study Eye.
4. CST of ≥ 320 microns on SD-OCT (Heidelberg Spectralis or equivalent on other OCT
instruments) as determined by the Reading Center
5. Decrease in vision determined by the Investigator to be primarily the result of ME
secondary to RVO.
6. Other protocol-specified inclusion criteria may apply.
Exclusion Criteria:
1. Macular edema in the Study Eye for reasons other than RVO
2. Active iris or angle neovascularization, neovascular glaucoma, neovascularization of
the optic disc, retinal neovascularization or vitreous hemorrhage in the Study Eye.
3. Uncontrolled glaucoma in the Study Eye.
4. Active retinal disease other than the condition under investigation in the Study Eye.
5. Any history or evidence of a concurrent ocular condition present, that in the opinion
of the Investigator could require either medical or surgical intervention alter visual
acuity during the study
6. Active or suspected ocular or periocular infection or inflammation
7. Any prior use of an approved or investigational treatment for macular edema secondary
to RVO in the Study Eye (e.g. anti-VEGF, intraocular or periocular steroids, macular
laser photocoagulation).
8. Women who are pregnant or lactating or intending to become pregnant during the study.
9. Uncontrolled blood pressure defined as a systolic value ≥ 180 mmHg or diastolic value
≥100 mmHg while at rest
10. Recent history (within the 6 months prior to screening) of myocardial infarction,
stroke, transient ischemic attack, acute congestive heart failure or any acute
coronary event.
11. History of a medical condition that, in the judgment of the Investigator, would
preclude scheduled study visits, completion of the study, or a safe administration of
investigational product.
12. Other protocol-specified exclusion criteria may apply.
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Recruiting
A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO)
This Phase 3 study will evaluate the efficacy, durability, and safety of KSI-301 compared to aflibercept, in participants with macular edema due to treatment-naïve branch (BRVO) or central retinal vein occlusion (CRVO).
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: KSI-301
- drug: Aflibercept
- other: Sham Procedure
Eligibility
Inclusion Criteria:
1. Signed informed consent prior to participation in the study.
2. Treatment-naïve macular edema of 6 months duration or less due to CRVO or BRVO.
Participants with hemiretinal vein occlusion will be included as CRVO.
3. BCVA ETDRS letter score between 80 and 25 (20/25 to 20/320 Snellen equivalent),
inclusive in the Study Eye.
4. CST of ≥ 320 microns on SD-OCT (Heidelberg Spectralis or equivalent on other OCT
instruments) as determined by the Reading Center
5. Decrease in vision determined by the Investigator to be primarily the result of ME
secondary to RVO.
6. Other protocol-specified inclusion criteria may apply.
Exclusion Criteria:
1. Macular edema in the Study Eye for reasons other than RVO
2. Active iris or angle neovascularization, neovascular glaucoma, neovascularization of
the optic disc, retinal neovascularization or vitreous hemorrhage in the Study Eye.
3. Uncontrolled glaucoma in the Study Eye.
4. Active retinal disease other than the condition under investigation in the Study Eye.
5. Any history or evidence of a concurrent ocular condition present, that in the opinion
of the Investigator could require either medical or surgical intervention alter visual
acuity during the study
6. Active or suspected ocular or periocular infection or inflammation
7. Any prior use of an approved or investigational treatment for macular edema secondary
to RVO in the Study Eye (e.g. anti-VEGF, intraocular or periocular steroids, macular
laser photocoagulation).
8. Women who are pregnant or lactating or intending to become pregnant during the study.
9. Uncontrolled blood pressure defined as a systolic value ≥ 180 mmHg or diastolic value
≥100 mmHg while at rest
10. Recent history (within the 6 months prior to screening) of myocardial infarction,
stroke, transient ischemic attack, acute congestive heart failure or any acute
coronary event.
11. History of a medical condition that, in the judgment of the Investigator, would
preclude scheduled study visits, completion of the study, or a safe administration of
investigational product.
12. Other protocol-specified exclusion criteria may apply.
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Recruiting